LOGIN  |  REGISTER
Cue Biopharma
Assertio

Butterfly Network to Present at 33rd Annual Oppenheimer Healthcare Conference

March 08, 2023 | Last Trade: US$3.12 0.40 -11.36

BURLINGTON, Mass. / Mar 08, 2023 / Business Wire / Butterfly Network, Inc. (NYSE: BFLY) ("Butterfly"), a digital health company transforming care with handheld, whole-body ultrasound, today announced that it will participate in the 33rd Annual Oppenheimer Healthcare Conference taking place virtually on March 13-15, 2023. Heather Getz, Executive Vice President & Chief Financial Officer, Darius Shahida, Chief Strategy Officer & Chief Business Development Officer, and Dr. John Martin, Chief Medical Officer will present on March 14, 2023 at 10:40am Eastern Time.

A live webcast of the presentation will be available in the Events & Presentations section of the Butterfly Network investor website.

About Butterfly Network

Founded by Dr. Jonathan Rothberg in 2011 and listed on the New York Stock Exchange through a business combination with Longview Acquisition Corp., Butterfly created the world's first handheld, single probe whole-body ultrasound system using semiconductor technology, the Butterfly iQ+. Butterfly's mission is to democratize medical imaging and contribute to the aspiration of global health equity, making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Through its proprietary Ultrasound-on-Chip™ technology, Butterfly is paving the way for earlier detection and remote management of health conditions around the world. The Butterfly iQ+ can be purchased today by trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, North America and South America; to learn more about available countries, visit: butterflynetwork.com/choose-your-country. Butterfly iQ+ is a prescription device intended for trained healthcare professionals only.

Viking Therapeutics

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB